A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).
Edith A. Perez
No relevant relationships to disclose
Jose Manuel Lopez-Vega
Consultant or Advisory Role - Roche
Lucia Del Mastro
Honoraria - Roche
Thierry Petit
Consultant or Advisory Role - Roche (U)
Lada Mitchell
Employment or Leadership Position - Roche
Christina H. Pelizon
Employment or Leadership Position - Roche
Stock Ownership - Roche
Michael Andersson
Honoraria - Roche